Stockscreener 앱 받기
1.43
0.00%
0.00
Galmed Pharmaceuticals Ltd 주식(GLMD)의 최신 뉴스
Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond Nash - marketscreener.com
Galmed Pharmaceuticals Unveils Biomarker Signature for Aramchol, Expanding Market Potential - TipRanks
Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH - WV News
Wall Street Zen Upgrades Galmed Pharmaceuticals (NASDAQ:GLMD) to Sell - Defense World
Galmed Pharmaceuticals: Q1 Earnings Snapshot - New Haven Register
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Galmed Pharmaceuticals Reports Q1 2025 Financial Results and Advances in Oncology - TipRanks
Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - PR Newswire
Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated at StockNews.com - Defense World
Galmed Pharmaceuticals Unveils Promising Aramchol Results in PSC Models - TipRanks
Galmed (GLMD) Announces Promising Pre-Clinical Results for Aramc - GuruFocus
Galmed (GLMD) Announces Promising Pre-Clinical Results for Aramchol in Treating PSC | GLMD Stock News - GuruFocus
Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models - PR Newswire
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
Galmed Pharmaceuticals Ltd’s Market Journey: Closing Weak at 1.29, Down -11.64 - DWinneX
Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by Analysts at StockNews.com - Defense World
Galmed Pharma Shares Jump 10% On Cancer Drug Data: Retail Traders Turn ‘Extremely Bullish’ By Stocktwits - Investing.com India
GLMD Advances Cancer Treatment with Promising Aramchol Results | GLMD Stock News - GuruFocus
GLMD: Galmed's Aramchol Boosts Cancer Drug Efficacy in Early Studies | GLMD Stock News - GuruFocus
Galmed Pharmaceuticals Unveils Promising Oncology Study Results with Aramchol - TipRanks
Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models - PR Newswire
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Up 41.3% in April - Defense World
Galmed Pharmaceuticals Ltd (GLMD) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Sete News
Understanding the Risks of Investing in Galmed Pharmaceuticals Ltd (GLMD) - knoxdaily.com
Galmed Pharmaceuticals (NASDAQ:GLMD) Shares Cross Below 200 Day Moving Average – What’s Next? - Defense World
StockNews.com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD) - Defense World
Galmed Pharmaceuticals (GLMD) Collaborates with VCU to Tackle GI Cancer Drug Resistance - GuruFocus
GLMD’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Understanding GLMD stock ratios for better investment decisions - uspostnews.com
Crude Oil Down 2%; Roper Technologies Increases 2025 Outlook - Benzinga
Is Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) Stock Worth Investing In for High Returns? - Marketing Sentinel
Galmed Signs Term Sheet to Develop New Semaglutide Formulation; Shares Up - marketscreener.com
Galmed (GLMD) Shares Climb Amid Strategic Drug Delivery Development - Stocks Telegraph
Galmed Pharmaceuticals Signs Agreement for Novel Semaglutide Formulation - TipRanks
Galmed (GLMD) Pharmaceuticals Signs Licensing Agreement for Drug - GuruFocus
Galmed Signed Term Sheet For The Development Of Novel Semaglutide Sublingual Formulation - marketscreener.com
Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation - PR Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Galmed partners with VCU to target drug resistance - The Pharma Letter
Galmed Pharmaceuticals Partners with VCU to Combat Drug Resistance in GI Cancers - TipRanks
Galmed Pharmaceuticals Launches VCU Collaboration To Tackle Drug Resistance In Gi Cancers - marketscreener.com
Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers - PR Newswire
Galmed reports key biomarkers for heart and liver health By Investing.com - Investing.com South Africa
Galmed Pharmaceuticals Unveils New Blood Markers for Aramchol - TipRanks
Galmed reports key biomarkers for heart and liver health - Investing.com
Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor - Kilgore News Herald
Galmed Pharmaceuticals Reports Positive Results from AM-001 Study of Aramchol Meglumine - TipRanks
Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor - PR Newswire
Maxim Group Reiterates “Hold” Rating for Galmed Pharmaceuticals (NASDAQ:GLMD) - Defense World
1.89%
3.74%
자본화:
|
볼륨(24시간):